Trial Profile
Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: An observational, retrospective study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 14 Oct 2019 Results (Data cut off 15 Jun 2016) assessing long-term response after vismodegib discontinuation were published in the Journal of Clinical Oncology
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology